Human Biology.
Miniaturized.
Microphysiological systems (MPS) recreating human organ function for FDA 3.0 compliant drug development. Replace animal testing with human-relevant data.
MPS Core Principles
Engineering human tissue models that recapitulate in vivo physiology.
Physiological Flow
Microfluidic channels delivering nutrients and drugs under physiologically relevant shear stress and flow rates.
3D Architecture
Tissue-engineered constructs maintaining native cell-cell and cell-matrix interactions in three dimensions.
Multi-Organ Linking
Interconnected organ modules enabling systemic ADME-Tox and drug-drug interaction studies.
Human Primary Cells
Patient-derived or iPSC-derived cells maintaining human-specific drug responses and metabolism.
Real-Time Monitoring
Integrated sensors for continuous measurement of TEER, oxygen, glucose, and biomarkers.
Scalable & Reproducible
Standardized manufacturing for consistent, high-throughput drug screening applications.
Available Organ Systems
Comprehensive human tissue models for every drug development need.
FDA 3.0 Ready
The FDA Modernization Act 2.0 (2022) removed the animal testing mandate, opening the door for MPS as New Approach Methodologies (NAMs).
- ISTAND qualification pathway
- ICH M3/S7 guideline acceptance
- EMA and PMDA alignment
- Fit-for-purpose validation
Industry Leaders
Organizations pioneering human MPS technology.
Own the MPS Platform
HumanMPS.com - the definitive domain for microphysiological systems and FDA 3.0 drug development.
Inquire About This Domain